Skip to main content

Advertisement

SpringerLink
Log in

Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review

  • Review Article
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Introduction

This systematic review assesses the effectiveness of intravitreal bevacizumab (IVB) versus a comparison group in the treatment of branch retinal vein occlusion (BRVO)-associated macular edema, and explores its effects on visual acuity (VA) and central macular thickness (CMT).

Methods

The authors searched the following databases: Medline (1950–October week 3, 2011), The Cochrane Library (Issue 10, 2011), EMBASE (up to 24 October 2011), and the TRIP Database (up to 24 October 2011), using no language or other limits. Trials that were included consisted of patients with BRVO-associated macular edema, those comparing a 1.25 mg IVB injection with a comparison group, those reporting both VA and CMT outcomes, and those having a minimum follow-up of 4 weeks.

Results

In the four trials comparing IVB with a comparison group, IVB was effective in improving VA and CMT values in the long-term (12 weeks) in patients with BRVO-associated macular edema. Furthermore, statistically significant improvements in VA in the short-term (4 weeks) could also be seen.

Discussion

Clinicians should use this review as an indicator that IVB is effective in improving VA and CMT values in the long-term in patients with BRVO-associated macular edema. It is important to note, however, that statistically significant improvements in VA in the short term could be seen. This review's main aim was to serve as an evidence base for potentially using other modalities, such as IVB, which seems to be reserved for certain cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. David R, Zangwill L, Badarna M, Yassur Y (1988) Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 197(2):69–74

    Article  PubMed  CAS  Google Scholar 

  2. Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133–141, discussion 141–133

    PubMed  CAS  Google Scholar 

  3. Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114(10):1243–1247

    Article  PubMed  CAS  Google Scholar 

  4. Laouri M, Chen E, Looman M, Gallagher M (2011) The burden of disease of retinal vein occlusion: review of the literature. Eye 25(8):981–988

    Article  PubMed  CAS  Google Scholar 

  5. Moradian S, Faghihi H, Sadeghi B, Piri N, Ahmadieh H, Soheilian M, Dehghan MH, Azarmina M, Esfahani MR (2011) Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefes Arch Clin Exp Ophthalmol 249(2):193–200

    Article  PubMed  CAS  Google Scholar 

  6. Ehlers JP, Fekrat S (2011) Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 56(4):281–299

    Article  PubMed  Google Scholar 

  7. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98(3):271–282

    Google Scholar 

  8. McIntosh RL, Mohamed Q, Saw SM, Wong TY (2007) Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114(5):835–854

    Article  PubMed  Google Scholar 

  9. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50(3):1025–1032

    Article  PubMed  Google Scholar 

  10. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, Mishima HK (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 22(1):42–48

    Article  PubMed  CAS  Google Scholar 

  11. Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger S (2008) Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92(3):351–355

    Article  PubMed  CAS  Google Scholar 

  12. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92(4):518–522

    Article  PubMed  CAS  Google Scholar 

  13. Chen CH, Chen YH, Wu PC, Chen YJ, Lee JJ, Liu YC, Kuo HK (2010) Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Med J 33(4):424–435

    PubMed  Google Scholar 

  14. Micieli JA, Micieli A, Smith AF (2010) Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can J Ophthalmol 45(3):231–238

    Article  PubMed  Google Scholar 

  15. Dickersin K, Scherer R, Lefebvre C (1994) Identifying relevant studies for systematic reviews. BMJ 309(6964):1286–1291

    Article  PubMed  CAS  Google Scholar 

  16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12

    Article  PubMed  CAS  Google Scholar 

  17. Higgins J, Green S (2006) Cochrane Handbook for Systematic Reviews of Interventions 4.2.6: Section 6. The Cochrane Library 4

  18. Çekiç O, Cakir M, Yazici AT, Alagoz N, Bozkurt E, Faruk Yilmaz O (2010) A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res 35(10):925–929

    Article  PubMed  Google Scholar 

  19. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 29(4):511–515

    Article  PubMed  Google Scholar 

  20. Wu WC, Cheng KC, Wu HJ (2009) Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 23(12):2215–2222

    Article  PubMed  CAS  Google Scholar 

  21. Fung AE, Bhisitkul RB (2008) Safety monitoring with ocular anti-vascular endothelial growth factor therapies. Br J Ophthalmol 92(12):1573–1574

    Article  PubMed  Google Scholar 

  22. Network Diabetic Retinopathy Clinical Research, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114(10):1860–1867

    Article  Google Scholar 

  23. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908

    Article  PubMed  CAS  Google Scholar 

  24. Roth DB, King A, Weiss M, Klein D (2009) Systemic adverse events after bevacizumab. Ophthalmology 116(6):1226 e1221

    Article  Google Scholar 

  25. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Peyman GA (2009) Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116(6):1142–1150

    Article  PubMed  Google Scholar 

  26. Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, Lavaque AJ, Larson RJ (2009). Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 116(5):902–911, quiz 912–903

    Article  PubMed  Google Scholar 

  27. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602

    Article  PubMed  Google Scholar 

  28. Sacu S, Pemp B, Weigert G, Matt G, Garhofer G, Pruente C, Schmetterer L, Schmidt-Erfurth U (2011) Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 52(6):3046–3050

    Article  PubMed  CAS  Google Scholar 

  29. Gillies MC (2006) What we don't know about Avastin might hurt us. Arch Ophthalmol 124(10):1478–1479

    Article  PubMed  Google Scholar 

  30. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28(2):131–138

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Vanguard Medical Associates, Department of Visual Services, 133 Brookline Avenue, Boston, MA, 02215, USA

    Taygan Yilmaz

  2. Department of Ophthalmology, Hospital de León, León, Spain

    Miguel Cordero-Coma

Authors
  1. Taygan Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miguel Cordero-Coma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taygan Yilmaz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yilmaz, T., Cordero-Coma, M. Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol 250, 787–793 (2012). https://doi.org/10.1007/s00417-012-2016-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-012-2016-6

Keywords

Search

Navigation